SERPINA5抗体 新品

+ +

•  

   

     Gel: 10%SDS-PAGE, Lysate: 40 μg, Lane 1-2: Human liver cancer tissue, A549 cells, Primary antibody: P07715(SERPINA5 Antibody) at dilution 1/750, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human lung cancer tissue using P07715(SERPINA5 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

The SERPINA5 antibody is designed to target SERPINA5. a member of the serine protease inhibitor (serpin) superfamily, also known as protein C inhibitor (PCI). SERPINA5 is synthesized primarily in the liver and plays a regulatory role in coagulation, fibrinolysis, and inflammatory responses by inhibiting proteases like activated protein C (APC), thrombin, and plasmin. Its involvement in these pathways links it to conditions such as thrombosis, cancer progression, and reproductive biology.

SERPINA5 antibodies are essential tools for detecting and quantifying SERPINA5 protein levels in research. These antibodies, often produced in rabbits or mice using recombinant SERPINA5 or synthetic peptides, are validated for specificity in techniques such as Western blotting, immunohistochemistry (IHC), and ELISA. Studies utilizing these antibodies have revealed SERPINA5's dual role: it exhibits anticoagulant properties by modulating APC activity but may also promote tumor invasion by interacting with extracellular matrix components. Dysregulation of SERPINA5 has been observed in cancers, cardiovascular diseases, and infertility, highlighting its potential as a diagnostic or prognostic biomarker.

Ongoing research focuses on its therapeutic implications, particularly in balancing hemostatic disorders and targeting cancer metastasis. Validated SERPINA5 antibodies remain critical for elucidating its complex functions in health and disease.